Erratum to "Créhange G, Roach III M, Martin É, Cormier L, Peiffert D, Cochet A, et al. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?" [Cancer Radiother. 18 (2014) 524-34], 10.1016/j.canrad.2014.07.153;Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how?

Cancer/Radiotherapie

Volumn 18, Issue 5-6, 2014, Pages 524-534

  Crehange G ^a,b   Roach, M ^c   Martin, E ^a   Cormier, L ^d   Peiffert, D ^e   Cochet, A ^a,b,d   Chapet, O ^f   Supiot, S ^g   Cosset, J M ^h   Bolla, M ⁱ   Chung, H T ^j  

^a CENTRE GEORGES FRANÇOIS LECLERC   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HÔPITAL DU BOCAGE   (France)

^e Service d'anatomie pathologique Institut de cancérologie de Lorraine   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g Institut de cancérologie de l'Ouest René Gauducheau ^*  (France)

^h INSTITUT CURIE   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

more..

Author keywords

Local failure; Oligometastases; Prostate cancer; Salvage brachytherapy; Salvage radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; BRACHYTHERAPY; CANCER RECURRENCE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LOCAL RECURRENCE FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; SALVAGE REIRRADIATION; SALVAGE THERAPY; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT FAILURE; WHOLE BODY CT; WHOLE BODY PET; ADENOCARCINOMA; BLOOD; BONE NEOPLASMS; LYMPHATIC METASTASIS; MALE; MULTICENTER STUDY (TOPIC); MULTIMODAL IMAGING; MULTIMODALITY CANCER THERAPY; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE THERAPY; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSURGERY; RADIOTHERAPY; SECONDARY;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MULTICENTER STUDIES AS TOPIC; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, IMAGE-GUIDED; RADIOTHERAPY, INTENSITY-MODULATED; SALVAGE THERAPY;

EID: 84907394449     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2014.10.001     Document Type: Erratum

References (74)

1. Beckendorf V., Guérif S., Le Prisé E., Cosset J.M., Bougnoux A., Chauvet B., et al. 70Gy versus 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011, 80:1056-1063.
2. Dearnaley D.P., Sydes M.R., Graham J.D., Aird E.G., Bottomley D., Cowan R.A., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
3. Peeters S.T., Heemsbergen W.D., Koper P.C., van Putten W.L., Slot A., Dielwart M.F., et al. Dose response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24:1990-1996.
4. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., et al. Prostate cancer radiation dose response: results of the MD. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
5. Zelefsky M.J., Yamada Y., Fuks Z., Zhang Z., Hunt M., Cahlon O., et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71:1028-1033.
6. Haider M.A., Chung P., Sweet J., Toi A., Jhaveri K., Menard C., et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:425-430.
7. Dinniwell R., Chan P., Czarnota G., Haider M.A., Jhaveri K., Jewett M., et al. Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009, 74:844-851.
8. Coen J.J., Zietman A.L., Thakral H., Shipley W.U. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002, 20:3199-3205.
9. Ladjevardi S., Berglund A., Varenhorst E., Bratt O., Widmark A., Sandblom G. Treatment with curative intent and survival in men with high-risk prostate cancer. A population-based study of 11380 men with serum PSA level 20-100ng/mL. BJU Int 2013, 111:381-388.
10. Warde P., Mason M., Ding K., Kirkbride P., Brundage M., Cowan R., et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011, 378:2104-2111.
11. Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
12. Martin J.M., Handorf E.A., Kutikov A., Uzzo R.G., Bekelman J.E., Horwitz E.M., et al. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer 2014, 120:2114-2121.
13. Agarwal P.K., Sadetsky N., Konety B.R., Resnick M.I., Carroll P.R. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer 2008, 112:307-314.
14. Pucar D., Hricak H., Shukla-Dave A., Kuroiwa K., Drobnjak M., Eastham J., et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys 2007, 69:62-69.
15. Huang W.C., Kuroiwa K., Serio A.M., Bianco F.J., Fine S.W., Shayegan B., et al. The anatomical and pathological characteristics of irradiated prostate cancers may influence the oncological efficacy of salvage ablative therapies. J Urol 2007, 177:1324-1329. [quiz 591].
16. Leibovici D., Chiong E., Pisters L.L., Guo C.C., Ward J.F., Andino L., et al. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol 2012, 188:98-102.
17. Lepinoy A., Cochet A., Cueff A., Cormier L., Martin E., Maingon P., et al. Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy. Radiother Oncol 2014, 111:120-125.
18. Arrayeh E., Westphalen A.C., Kurhanewicz J., Roach M., Jung A.J., Carroll P.R., et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys 2012, 82:e787-e793.
19. Chopra S., Toi A., Taback N., Evans A., Haider M.A., Milosevic M., et al. Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:e441-e448.
20. Aaronson D.S., Yamasaki I., Gottschalk A., Speight J., Hsu I.C., Pickett B., et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009, 104:600-604.
21. Allen G.W., Howard A.R., Jarrard D.F., Ritter M.A. Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 2007, 110:1405-1416.
22. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999, 54:880-883.
23. Burri R.J., Stone N.N., Unger P., Stock R.G. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:1338-1344.
24. Grado G.L. Benefits of brachytherapy as salvage treatment for radio recurrent localized prostate cancer. Urology 1999, 54:204-207.
25. Hsu C.C., Hsu H., Pickett B., Créhange G., Hsu I.C., Dea R., et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:370-377.
26. Moman M.R., van der Poel H.G., Battermann J.J., Moerland M.A., van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 2010, 9:119-125.
27. Sasaki H., Kido M., Miki K., Kuruma H., Takahashi H., Aoki M., et al. Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy. Int J Urol 2014, 21:572-577.
28. Chen C.P., Weinberg V., Shinohara K., Roach M., Nash M., Gottschalk A., et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys 2013, 86:324-329.
29. Jo Y., Fujii T., Hara R., Yokoyama T., Miyaji Y., Yoden E., et al. Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy - preliminary results. BJU Int 2012, 109:835-839.
30. Yamada Y., Kollmeier M.A., Pei X., Kan C.C., Cohen G.N., Donat S.M., et al. A Phase II study of salvage high-dose rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 2014, 13:111-116.
31. Nguyen P.L., D'Amico A.V., Lee A.K., Suh W.W. Patient selection, cancer control, and complications after salvage local therapy for post-radiation prostate specific antigen failure: a systematic review of the literature. Cancer 2007, 110:1417-1428.
32. Peters M., Maenhout M., van der Voort van Zyp J.R., Moerland M.A., Moman M.R., Steuten L.M., et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol 2014.
33. Mahal B.A., Ziehr D.R., Hyatt A.S., Neubauer-Sugar E.H., O'Farrell D.A., O'Leary M.P., et al. Use of a rectal spacer with low-dose rate brachytherapy for treatment of prostate cancer in previously irradiated patients: initial experience and short-term results. Brachytherapy 2014.
34. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999, 43:1095-1101.
35. Miralbell R., Roberts S.A., Zubizarreta E., Hendry J.H. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: alpha/beta=1.4 (0.9-2.2)Gy. Int J Radiat Oncol Biol Phys 2012, 82:e17-e24.
36. Dolinsky C., Glatstein E. Some cases of severe normal tissue toxicity can be anticipated with ablated fractionated radiation with appropriate long-term follow-up. Semin Radiat Oncol 2008, 18:229-233.
37. Vavassori A., Jereczek-Fossa B.A., Beltramo G., De Cicco L., Fariselli L., Bianchi L.C., et al. Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 2010, 96:71-75.
38. Jereczek-Fossa B.A., Beltramo G., Fariselli L., Fodor C., Santoro L., Vavassori A., et al. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:889-897.
39. Passoni N.M., Abdollah F., Suardi N., Gallina A., Bianchi M., Tutolo M., et al. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. Urol Oncol 2014, 32:29e1-29e8.
40. Scattoni V., Picchio M., Suardi N., Messa C., Freschi M., Roscigno M., et al. Detection of lymph node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52:423-429.
41. Suardi N., Gandaglia G., Gallina A., Di Trapani E., Scattoni V., Vizziello D., et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 2014.
42. Meijer H.J., van Lin E.N., Debats O.A., Witjes J.A., Span P.N., Kaanders J.H., et al. High occurrence of aberrant lymph node spread on magnetic resonance lymphography in prostate cancer patients with a biochemical recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 2012, 82:1405-1410.
43. Vermeeren L., Meinhardt W., van der Poel H.G., Valdes Olmos R.A. Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer. Eur J Nucl Med Mol Imaging 2010, 37:2021-2026.
44. Ceci F., Castellucci P., Graziani T., Schiavina R., Brunocilla E., Mazzarotto R., et al. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 2014, 41:878-886.
45. Créhange G., Chen C.P., Hsu C.C., Kased N., Coakley F.V., Kurhanewicz J., et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm. Cancer Treat Rev 2012, 38:956-967.
46. Giovacchini G., Picchio M., Garcia-Parra R., Briganti A., Abdollah F., Gianolli L., et al. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen deprivation therapy. J Nucl Med 2014, 55:233-241.
47. Park H., Wood D., Hussain H., Meyer C.R., Shah R.B., Johnson T.D., et al. Introducing parametric fusion PET/MRI of primary prostate cancer. J Nucl Med 2012, 53:546-551.
48. Chondrogiannis S., Marzola M.C., Ferretti A., Maffione A.M., Rampin L., Grassetto G., et al. Role of (1)(8)F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging 2013, 40:1356-1364.
49. Breeuwsma A.J., Pruim J., van den Bergh A.C., Leliveld A.M., Nijman R.J., Dierckx R.A., et al. Detection of local, regional, and distant recurrence in patients with psa relapse after external beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010, 77:160-164.
50. Fortuin A.S., Deserno W.M., Meijer H.J., Jager G.J., Takahashi S., Debats O.A., et al. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Int J Radiat Oncol Biol Phys 2012, 84:712-718.
51. Meijer H.J., Debats O.A., Kunze-Busch M., van Kollenburg P., Leer J.W., Witjes J.A., et al. Magnetic resonance lymphography-guided selective high-dose lymph node irradiation in prostate cancer. Int J Radiat Oncol Biol Phys 2012, 82:175-183.
52. Iversen P., Roder M.A. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer. Expert Rev Anticancer Ther 2008, 8:361-369.
53. Ahmed K.A., Barney B.M., Davis B.J., Park S.S., Kwon E.D., Olivier K.R. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2012, 2:215.
54. Berkovic P., De Meerleer G., Delrue L., Lambert B., Fonteyne V., Lumen N., et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 2013, 11:27-32.
55. Decaestecker K., De Meerleer G., Lambert B., Delrue L., Fonteyne V., Claeys T., et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 2014, 9:135.
56. Jereczek-Fossa B.A., Fariselli L., Beltramo G., Catalano G., Serafini F., Garibaldi C., et al. Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 2009, 93:14-17.
57. Schick U., Jorcano S., Nouet P., Rouzaud M., Vees H., Zilli T., et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol 2013, 52:1622-1628.
58. De Bari B., Alongi F., Lestrade L., Giammarile F. Choline PET in prostate cancer management: the point of view of the radiation oncologist. Critical Rev Oncol Hematol 2014.
59. Mottet N., Peneau M., Mazeron J.J., Molinié V., Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012, 62:213-219.
60. Widmark A., Klepp O., Solberg A., Damber J.E., Angelsen A., Fransson P., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
61. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
62. Hanks G.E., Pajak T.F., Porter A., Grignon D., Brereton H., Venkatesan V., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
63. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997, 15:1013-1021.
64. Formenti S.C., Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10:718-726.
65. Harris T.J., Hipkiss E.L., Borzillary S., Wada S., Grosso J.F., Yen H.R., et al. Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate 2008, 68:1319-1329.
66. Demaria S., Ng B., Devitt M.L., Babb J.S., Kawashima N., Liebes L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58:862-870.
67. Bhattasali O., Chen L.N., Tong M., Lei S., Collins B.T., Krishnan P., et al. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naive prostate cancer. Front Oncol 2013, 3:293.
68. Greco C., Zelefsky M.J., Lovelock M., Fuks Z., Hunt M., Rosenzweig K., et al. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol Biol Phys 2011, 79:1151-1157.
69. Muacevic A., Kufeld M., Rist C., Wowra B., Stief C., Staehler M. Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 2013, 31:455-460.
70. Crook J.M., O'Callaghan C.J., Duncan G., Dearnaley D.P., Higano C.S., Horwitz E.M., et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012, 367:895-903.
71. Hussain M., Tangen C.M., Berry D.L., Higano C.S., Crawford E.D., Liu G., et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013, 368:1314-1325.
72. Stephenson A.J., Scardino P.T., Kattan M.W., Pisansky T.M., Slawin K.M., Klein E.A., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25:2035-2041.
73. Nguyen P.L., Chen M.H., D'Amico A.V., Tempany C.M., Steele G.S., Albert M., et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007, 110:1485-1492.
74. Lee B., Shinohara K., Weinberg V., Gottschalk A.R., Pouliot J., Roach M., et al. Feasibility of high-dose rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.